This large Swedish population-based cohort study used national registry data from 2007–2019, including over 1.3 million singleton births. It compared babies born to mothers who used SSRIs in pregnancy with those who did not use antidepressants. SSRI exposure was identified through prescription records, with attention to late-pregnancy use. Primary outcomes were Apgar scores at 1 and 5 minutes after birth, including the risk of scores below 7 and very low scores (0–3).
SSRI exposure, especially in late pregnancy, was associated with a small increase in the odds of low Apgar scores (e.g., <7) and very low scores (0–3) at 1 and 5 minutes. On average, the difference in Apgar scores between exposed and unexposed babies was about 0.1–0.2 points—statistically significant but clinically small. Most babies, even with SSRI exposure, still had Apgar scores in the normal range. The authors adjusted for many maternal factors (age, psychiatric history, smoking, BMI), and the association persisted, suggesting a possible independent drug effect but not proving causation.
The study is observational, so it cannot prove that SSRIs themselves cause lower Apgar scores; underlying depression, anxiety, or other health issues may be driving some of the risk. Exposure was based on prescription fills, which may not match actual intake, dose changes, or timing precisely. Important factors like symptom severity, therapy use, social stress, nutrition, and substance use are imperfectly measured in registries. The Swedish population and health system may limit direct generalization to other settings, and short-term Apgar scores do not predict long-term neurodevelopmental outcomes on their own, which were not assessed in this paper.
This is a robust, registry-based cohort with very large numbers and good statistical power, which strengthens confidence in the observed associations. However, observational design means residual confounding is likely, especially confounding by indication (severity of maternal mental illness, stress, comorbidities), which are difficult to fully capture in registries. The small absolute risk increase and minimal mean Apgar score differences suggest that, for most pregnancies, SSRI use is compatible with healthy neonatal adaptation, aligning with prior literature showing modest neonatal adaptation effects rather than major harm. Overall, the data support careful, individualized risk–benefit discussions rather than routine discontinuation of SSRIs in pregnancy, and they fit with broader evidence that untreated maternal mood disorders carry their own obstetric and neonatal risks.
Patients using SSRIs in pregnancy should not stop medication suddenly; changes should only be made with their prescribing clinician and obstetric provider. Discuss with your clinician whether your current SSRI, dose, and timing are still the best choice given your mental health needs and pregnancy stage. Support whole-person health: sleep, nutrition, inflammation, thyroid and metabolic evaluation, and relational support can help lower overall stress on you and your baby. If you use SSRIs into late pregnancy, your birth team may monitor your baby a bit more closely right after birth, which mainly means extra observation, not that something is necessarily wrong.
This study looked at babies born to women who used SSRI antidepressants during pregnancy and compared their early health right after birth. Babies exposed to SSRIs, especially later in pregnancy, had slightly lower Apgar scores on average, but almost all still fell in the normal range, and the added risk of very low scores was small. This does not mean SSRIs are “unsafe” in pregnancy, but it does show there can be mild short-term effects on how a baby adjusts right after birth. For your fertility and pregnancy journey, it reinforces the need to treat mood symptoms seriously, look for root causes (sleep, hormones, thyroid, inflammation, past trauma), and make medication decisions together with a clinician who knows your story and goals.
The modest but consistent association between late-pregnancy SSRI use and lower Apgar scores, with evidence of dose–response, suggests a small neonatal adaptation effect consistent with prior reports (e.g., poor neonatal adaptation syndrome). Absolute risk increments are small; mean Apgar differences (~0.1–0.2) are unlikely to be clinically meaningful for most infants, but the tail risk of 0–3 scores is slightly higher and may matter in already high-risk pregnancies. For restorative care, prioritize comprehensive assessment of mood disorder drivers: thyroid panel (TSH, free T4, free T3, TPOAb), iron studies, B12/folate, Vitamin D, inflammatory markers as available, metabolic status (fasting glucose/insulin, lipids), sleep apnea screening in high-BMI patients, and cycle-related symptom patterns. In preconception counseling, discuss non-pharmacologic supports (psychotherapy, trauma work, exercise, circadian alignment, anti-inflammatory nutrition) and, when appropriate, dose optimization or switching agents before conception rather than abrupt cessation in late pregnancy. Coordinate with obstetrics/neonatology to ensure newborns exposed to SSRIs in the third trimester receive heightened immediate postnatal observation, while reassuring families that most infants do well and emphasizing that untreated maternal depression/anxiety also worsen obstetric outcomes.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.